Wells Fargo & Company Graybug Vision, Inc. Transaction History

Wells Fargo & Company

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.46 - $1.05 $1 - $3	3 Added 2.88%	107 $0
Q3 2022 Nov 14, 2022	BUY	$0.93 - $1.18 $13 - $17	15 Added 16.85%	104 $0
Q2 2022 Aug 12, 2022	BUY	$0.76 - $1.25 $6 - $10	8 Added 9.88%	89 $0
Q4 2021 Feb 14, 2022	BUY	$1.74 - $3.6 $1 - $3	1 Added 1.25%	81 $0
Q3 2021 Nov 15, 2021	BUY	$3.18 - $5.17 $133 - $217	42 Added 110.53%	80 $0
Q2 2021 Aug 16, 2021	SELL	$3.53 - $6.1 $7,056 - $12,193	-1,999 Reduced 98.13%	38 $0
Q1 2021 May 13, 2021	SELL	$5.55 - $35.0 $7,514 - $47,390	-1,354 Reduced 39.93%	2,037 $11,000
Q4 2020 Feb 09, 2021	BUY	$13.05 - $33.93 $44,252 - $115,056	3,391 New	3,391 $98,000

Ticker GRAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,517,700
Market Cap $63.5M
Description
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the t...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.